Back
Compare AU
Compare CURE vs. BNKS
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the Betashares Global Banks Currency Hedged ETF (BNKS). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | BNKS | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 84 | 77 |
Median incremental investment | $673.61 | $903.39 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,106.60 | $2,361.18 |
Average age group | > 35 | > 35 |
Key Summary
CURE | BNKS | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | BNKS.AX was created on 2016-07-28 by BetaShares. The fund's investment portfolio concentrates primarily on financials equity. BNKS.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global banks (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Moderna Inc (2.36 %) Twist Bioscience Corp (1.81 %) Natera Inc (1.80 %) | AUD - AUSTRALIA DOLLAR (0 %) BRL - BRAZILIAN REAL (0 %) CAD - CANADA DOLLAR (0 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Other (85.83 %) Communication Services (33.49 %) Financials (10.82 %) |
Top 3 countries | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) | United States (27.88 %) Canada (15.12 %) United Kingdom of Great Britain and Northern Ireland (10.54 %) |
Management fee | 0.45 % | 0.57 % |
Key Summary
CURE | BNKS | |
|---|---|---|
Issuer | Global X | BetaShares |
Tracking index | S&P Biotechnology Select Industry | Nasdaq Global ex-Australia Banks Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.57 % |
Price | $72.05 | $13.44 |
Size | $47.072 million | $191.404 million |
10Y return | N/A | 153.11 % |
Annual distribution yield (5Y) | 0.03 % | 2.47 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 01/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | BNKS | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 84 | 77 |
Median incremental investment | $673.61 | $903.39 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,106.60 | $2,361.18 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | BNKS | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | BNKS |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |